43
CordenPharma, a full-service CDMO, has announced its largest strategic investment to date with a committed spend of circa €900m (US$981m) over the next three years to grow its Peptide technology platform.
It plans two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions designed and built according to stringent quality and technical standards for short and long peptide manufacturing, including Biologics License Applications (BLA) requirements.
The US…